Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a significant stock price increase, rising over 7% and nearly 35% this week, indicating strong market interest and confidence in the company's future prospects [1] Company Developments - The company has obtained a medical device registration certificate for TONO-i from the National Medical Products Administration, which will be a key part of its glaucoma medical product portfolio [1] - TONO-i is designed to provide ophthalmologists with a tool to easily, accurately, and thoroughly monitor patients' intraocular pressure, thereby improving patient adherence to glaucoma medication treatment [1] - The introduction of TONO-i into the company's pipeline underscores its commitment to dual approaches in glaucoma management, focusing on both treatment and diagnosis [1] Strategic Partnerships - In November 2022, the company entered into an exclusive distribution agreement with C&VTech, a leading company in the field of glaucoma diagnostic, treatment, and prevention medical devices [1] - The agreement grants the company exclusive rights to register, import, promote, distribute, market, and sell TONO-i in Greater China, with rights later expanded to include Thailand and Malaysia, effective from August 2024 [1]
港股异动 | 兆科眼科-B(06622)再涨超7% 本周累涨近35% TONO-i眼压计获颁医疗器械注册证书